Recent advances in mantle cell lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop

Leo I. Gordon*, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas E. Witzig, Martin Dreyling

*Corresponding author for this work

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

Original languageEnglish (US)
Pages (from-to)2262-2270
Number of pages9
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • Immunotherapy
  • Lymphoma and Hodgkin disease
  • Marrow and stem cell transplant clinical results
  • Pharmacotherapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recent advances in mantle cell lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop'. Together they form a unique fingerprint.

  • Cite this